FDA District Office meeting
This article was originally published in The Gray Sheet
Scheduled for July 17 in New Orleans to discuss "good clinical practices in investigational product research." Topics to be discussed are requirements for conducting investigational research and "practical issues," including how to prepare for a data audit and what to expect during an investigation. The meeting is formatted for open dialogue between FDA and individuals involved in investigational product research. First priority for attendance will be given to individuals located in Louisiana and Mississippi. Call Rebecca Asente at 504/589-6344, ext. 158, for additional information...
You may also be interested in...
California-based biosensor patch company LifeSignals Group plans to file for an emergency use authorization from the US FDA for a new patch that can monitor vital signs to help individuals decide when to seek the help of a health care provider. See what LifeSignals’ CEO Surendar Magar said about it here.
Following the US request for ranitidine drugs to be withdrawn from the market, the European Medicines Agency says it would decide the fate of the products in the EU after wrapping up its own inquiry.
Perrigo will launch generics of GSK's OTC Voltaren Arthritis Pain drug later in 2020 following FDA approval of its ANDA. GSK, which received FDA's OTC switch approval in February, still hasn't launched the product or indicated when it will.